JP2020537528A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020537528A5 JP2020537528A5 JP2020521596A JP2020521596A JP2020537528A5 JP 2020537528 A5 JP2020537528 A5 JP 2020537528A5 JP 2020521596 A JP2020521596 A JP 2020521596A JP 2020521596 A JP2020521596 A JP 2020521596A JP 2020537528 A5 JP2020537528 A5 JP 2020537528A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- hla
- sequence
- locus
- endogenous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023015050A JP2023055884A (ja) | 2017-10-19 | 2023-02-03 | 改善された免疫細胞療法のためのｎｋ阻害物質遺伝子の標的指向遺伝子組み込み |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2017/076798 WO2018073391A1 (en) | 2016-10-19 | 2017-10-19 | Targeted gene insertion for improved immune cells therapy |
| EPPCT/EP2017/076798 | 2017-10-19 | ||
| EP2018053343 | 2018-02-09 | ||
| EPPCT/EP2018/053343 | 2018-02-09 | ||
| PCT/EP2018/055957 WO2019076486A1 (en) | 2017-10-19 | 2018-03-09 | TARGETED GENE INTEGRATION OF NK INHIBITOR GENES FOR ENHANCED IMMUNE CELL THERAPY |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023015050A Division JP2023055884A (ja) | 2017-10-19 | 2023-02-03 | 改善された免疫細胞療法のためのｎｋ阻害物質遺伝子の標的指向遺伝子組み込み |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020537528A JP2020537528A (ja) | 2020-12-24 |
| JP2020537528A5 true JP2020537528A5 (https=) | 2021-04-08 |
| JP7621795B2 JP7621795B2 (ja) | 2025-01-27 |
Family
ID=66173541
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020521596A Active JP7621795B2 (ja) | 2017-10-19 | 2018-03-09 | 改善された免疫細胞療法のためのｎｋ阻害物質遺伝子の標的指向遺伝子組み込み |
| JP2023015050A Pending JP2023055884A (ja) | 2017-10-19 | 2023-02-03 | 改善された免疫細胞療法のためのｎｋ阻害物質遺伝子の標的指向遺伝子組み込み |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023015050A Pending JP2023055884A (ja) | 2017-10-19 | 2023-02-03 | 改善された免疫細胞療法のためのｎｋ阻害物質遺伝子の標的指向遺伝子組み込み |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12209125B2 (https=) |
| EP (2) | EP3684919A1 (https=) |
| JP (2) | JP7621795B2 (https=) |
| KR (2) | KR20200075851A (https=) |
| CN (1) | CN111511903B (https=) |
| AU (2) | AU2018353112B2 (https=) |
| CA (1) | CA3084476A1 (https=) |
| IL (1) | IL273828B2 (https=) |
| MX (1) | MX2020004444A (https=) |
| WO (2) | WO2019076486A1 (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018189360A1 (en) * | 2017-04-13 | 2018-10-18 | Cellectis | New sequence specific reagents targeting ccr5 in primary hematopoietic cells |
| US20210130775A1 (en) * | 2017-08-02 | 2021-05-06 | Autolus Limited | Cells expressing a chimeric antigen receptor or engineered tcr and comprising a nucleotide sequence which is selectively expressed |
| KR20200075851A (ko) | 2017-10-19 | 2020-06-26 | 셀렉티스 | 개선된 면역 세포들 치료를 위한 nk 억제제들의 타겟인 유전자 통합 |
| EP3802578A4 (en) | 2018-06-01 | 2022-03-23 | Washington University | SUPPRESSION OF CYTOKINE RELEASE SYNDROME IN CHIMERIC ANTIGEN RECEPTOR CELL THERAPY |
| US12378572B2 (en) * | 2018-09-07 | 2025-08-05 | Crispr Therapeutics Ag | Universal donor cells |
| WO2020084034A1 (en) | 2018-10-26 | 2020-04-30 | F. Hoffmann-La Roche Ag | Multispecific antibody screening method using recombinase mediated cassette exchange |
| CN110055224B (zh) * | 2019-04-03 | 2023-06-30 | 深圳市体内生物医药科技有限公司 | 一种基因修饰的免疫细胞及其制备方法和应用 |
| MX2021013359A (es) | 2019-04-30 | 2022-01-31 | Crispr Therapeutics Ag | Terapia de celulas alogénicas de neoplasias malignas de células b usando células t modificadas genéticamente dirigidas a cd19. |
| CA3136742A1 (en) * | 2019-05-01 | 2020-11-05 | Juno Therapeutics, Inc. | Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods |
| WO2020261219A1 (en) * | 2019-06-27 | 2020-12-30 | Crispr Therapeutics Ag | Use of chimeric antigen receptor t cells and nk cell inhibitors for treating cancer |
| EP3992204A4 (en) * | 2019-06-28 | 2023-09-27 | CRAGE medical Co., Limited | CELL FOR RESISTANCE TO TRANSPLANT REACTION AND METHOD |
| PH12022550542A1 (en) * | 2019-09-05 | 2023-03-20 | Crispr Therapeutics Ag | Universal donor cells |
| CA3150235A1 (en) | 2019-09-05 | 2021-03-11 | Alireza Rezania | Universal donor cells |
| US20230127263A1 (en) * | 2019-09-20 | 2023-04-27 | The University Of North Carolina At Chapel Hill | Modified t cells and methods of preparing the same |
| KR20220141299A (ko) | 2020-01-14 | 2022-10-19 | 신테카인, 인크. | Il2 오르토로그 및 사용 방법 |
| JP2023529211A (ja) * | 2020-06-11 | 2023-07-07 | ノバルティス アーゲー | Ｚｂｔｂ３２阻害剤及びその使用 |
| US20230340067A1 (en) * | 2020-06-26 | 2023-10-26 | St. Jude Children's Research Hospital, Inc. | Methods of generating an activation inducible expression system in immune cells |
| WO2022020860A2 (en) * | 2020-07-24 | 2022-01-27 | Board Of Regents, The University Of Texas System | Engineered t cells and tumor-infiltrating lymphocytes to increase tumor killing |
| EP3943097A1 (en) * | 2020-07-24 | 2022-01-26 | AB2 Bio SA | Car-t cell therapy |
| WO2022112596A1 (en) | 2020-11-30 | 2022-06-02 | Cellectis Sa | Use of aminoquinoline compounds for higher gene integration |
| CN114874983A (zh) * | 2020-12-29 | 2022-08-09 | 博雅辑因（北京）生物科技有限公司 | 鉴定t细胞调节基因的方法 |
| WO2022144855A1 (en) | 2020-12-31 | 2022-07-07 | Crispr Therapeutics Ag | Universal donor cells |
| US20240197880A1 (en) * | 2021-04-30 | 2024-06-20 | Cellectis S.A. | New anti-muc1 cars and gene edited immune cells for solid tumors cancer immunotherapy |
| EP4365203A4 (en) * | 2021-07-01 | 2025-09-24 | Ningbo T Maximum Biopharmaceuticals Co Ltd | ANTIGEN-BINDING POLYPEPTIDE TARGETING B7H3 AND ITS APPLICATION |
| CN117940465A (zh) * | 2021-08-12 | 2024-04-26 | 苏州克睿基因生物科技有限公司 | 经修饰的细胞、其制备方法及应用 |
| EP4514363A4 (en) * | 2022-04-25 | 2026-04-22 | Univ Leland Stanford Junior | COMPOSITIONS AND METHODS FOR PREVENTING T LYMPHOCYTE DEPLETION |
| CN115820697B (zh) * | 2022-09-23 | 2024-07-30 | 中国海洋大学 | 一种免疫细胞及其制备方法和应用 |
| WO2024216346A1 (en) * | 2023-04-20 | 2024-10-24 | Peter Maccallum Cancer Institute | Compositions and methods for immunotherapy - ii |
| WO2024258835A1 (en) * | 2023-06-16 | 2024-12-19 | The Trustees Of Columbia University In The City Of New York | Removal of endogenous tcr chains for enhanced tcr-based immunotherapies |
| TW202509218A (zh) * | 2023-07-12 | 2025-03-01 | 亨利傑克森軍方醫學基金會 | 用於抑制自然殺手細胞之組合物及方法 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| FR2646438B1 (fr) | 1989-03-20 | 2007-11-02 | Pasteur Institut | Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration |
| WO1994024277A1 (en) | 1993-04-13 | 1994-10-27 | Sloan-Kettering Institute For Cancer Research | Protection of human bone marrow from high dose antifolate therapy using mutated human dihydrofolate reductase dna |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| WO1997033988A1 (en) | 1996-03-12 | 1997-09-18 | Sloan-Kettering Institute For Cancer Research | Double mutants of dihydrofolate reductase and methods of using same |
| CA2361191A1 (en) | 1999-02-03 | 2000-08-10 | The Children's Medical Center Corporation | Gene repair involving the induction of double-stranded dna cleavage at a chromosomal target site |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| KR20030032922A (ko) | 2000-02-24 | 2003-04-26 | 싸이트 테라피스 인코포레이티드 | 세포의 동시 자극 및 농축 |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| EP3202899B1 (en) | 2003-01-28 | 2020-10-21 | Cellectis | Custom-made meganuclease and use thereof |
| US9982251B2 (en) | 2003-03-14 | 2018-05-29 | Cellectis S.A. | Large volume ex vivo electroporation method |
| WO2011072246A2 (en) | 2009-12-10 | 2011-06-16 | Regents Of The University Of Minnesota | Tal effector-mediated dna modification |
| WO2012098238A1 (en) * | 2011-01-21 | 2012-07-26 | Novimmune S.A. | Combination therapies and methods using anti-cd3 modulating agents and anti-il-6 antagonists |
| CA3205636A1 (en) * | 2011-04-20 | 2012-10-26 | University Of Washington Through Its Center For Commercialization | Beta-2 microglobulin-deficient cells |
| BR112014029417B1 (pt) | 2012-05-25 | 2023-03-07 | Cellectis | Método ex vivo para a preparação de células t para imunoterapia |
| WO2013188873A1 (en) * | 2012-06-15 | 2013-12-19 | Gencia Corporation | Compositions and methods for enhancing immune responses |
| AU2013329186B2 (en) * | 2012-10-10 | 2019-02-14 | Sangamo Therapeutics, Inc. | T cell modifying compounds and uses thereof |
| WO2014191128A1 (en) * | 2013-05-29 | 2014-12-04 | Cellectis | Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system |
| JP6681837B2 (ja) * | 2014-03-11 | 2020-04-15 | セレクティスＣｅｌｌｅｃｔｉｓ | 同種移植に適合するｔ細胞を作製するための方法 |
| BR112017007003A2 (pt) * | 2014-10-07 | 2017-12-19 | Cellectis | método para modulação de atividade de células imunes induzidas por car |
| JP2018509148A (ja) * | 2015-03-11 | 2018-04-05 | セレクティスＣｅｌｌｅｃｔｉｓ | 患者における持続性および／または生着を増加させるために同種ｔ細胞を改変する方法 |
| EP4248744A3 (en) * | 2015-04-06 | 2023-12-27 | Regeneron Pharmaceuticals, Inc. | Humanized t cell mediated immune responses in non-human animals |
| CN107921148A (zh) * | 2015-05-08 | 2018-04-17 | 哈佛学院校长同事会 | 通用供体干细胞和相关方法 |
| GB2592821B (en) * | 2015-07-31 | 2022-01-12 | Univ Minnesota | Modified cells and methods of therapy |
| EP3350315A4 (en) * | 2015-09-18 | 2019-07-17 | The Regents of The University of California | METHOD FOR THE AUTOCATALYTIC GENOMIC PROCESSING AND NEUTRALIZATION OF AUTO CATALYTIC GENOMIC PROCESSING AND COMPOSITIONS THEREFOR |
| KR20250141836A (ko) * | 2015-11-04 | 2025-09-29 | 페이트 세러퓨틱스, 인코포레이티드 | 만능 세포의 유전자 조작 |
| US11815514B2 (en) | 2015-12-04 | 2023-11-14 | Juno Therapeutics, Inc. | Methods and compositions related to toxicity associated with cell therapy |
| EP3402495A4 (en) * | 2016-01-15 | 2019-06-19 | Etubics Corporation | METHOD AND COMPOSITIONS FOR T-CELL IMMUNOTHERAPY |
| JP2019532640A (ja) * | 2016-09-29 | 2019-11-14 | ナントクエスト インコーポレイテッド | 免疫原性が低下したｈｌａクラスｉ欠損ｎｋ−９２細胞 |
| CN106636090B (zh) * | 2016-10-11 | 2019-08-09 | 上海优卡迪生物医药科技有限公司 | 人源白细胞介素6的siRNA、重组表达CAR-T载体及其构建方法和应用 |
| CN108148863B (zh) * | 2016-12-05 | 2019-12-17 | 上海优卡迪生物医药科技有限公司 | 一种封闭il6r的用于缓解crs的car-t转基因载体及其构建方法和应用 |
| KR20200075851A (ko) | 2017-10-19 | 2020-06-26 | 셀렉티스 | 개선된 면역 세포들 치료를 위한 nk 억제제들의 타겟인 유전자 통합 |
-
2018
- 2018-03-09 KR KR1020207014099A patent/KR20200075851A/ko not_active Ceased
- 2018-03-09 EP EP18719441.0A patent/EP3684919A1/en active Pending
- 2018-03-09 CN CN201880082153.1A patent/CN111511903B/zh active Active
- 2018-03-09 KR KR1020247043433A patent/KR20250007705A/ko active Pending
- 2018-03-09 WO PCT/EP2018/055957 patent/WO2019076486A1/en not_active Ceased
- 2018-03-09 MX MX2020004444A patent/MX2020004444A/es unknown
- 2018-03-09 JP JP2020521596A patent/JP7621795B2/ja active Active
- 2018-03-09 US US16/755,082 patent/US12209125B2/en active Active
- 2018-03-09 AU AU2018353112A patent/AU2018353112B2/en active Active
- 2018-03-09 CA CA3084476A patent/CA3084476A1/en active Pending
- 2018-03-09 IL IL273828A patent/IL273828B2/en unknown
- 2018-04-16 WO PCT/EP2018/059692 patent/WO2019076489A1/en not_active Ceased
- 2018-04-16 US US16/755,093 patent/US12221478B2/en active Active
- 2018-04-16 EP EP18722412.6A patent/EP3673049A1/en active Pending
- 2018-04-16 AU AU2018351689A patent/AU2018351689B2/en active Active
-
2023
- 2023-02-03 JP JP2023015050A patent/JP2023055884A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020537528A5 (https=) | ||
| JP2023055884A5 (https=) | ||
| JP7590015B2 (ja) | 低抗原性細胞の製造方法 | |
| CN107630006B (zh) | 一种制备tcr与hla双基因敲除的t细胞的方法 | |
| AU2019261783B2 (en) | MND promoter chimeric antigen receptors | |
| US20220170097A1 (en) | Car t cell transcriptional atlas | |
| CN110358736B (zh) | 一种修饰的k562细胞、其制备方法及nk细胞培养组合物 | |
| JP2021534783A (ja) | キメラ抗原受容体発現細胞を作製する方法 | |
| JP2019536447A5 (https=) | ||
| Berger et al. | Adoptive transfer of virus-specific and tumor-specific T cell immunity | |
| US20170304418A1 (en) | Universal donor checkpoint inhibitor silenced/gene edited cord blood killer cells | |
| TW201920661A (zh) | 一種基因編輯t細胞及其用途 | |
| US20170020922A1 (en) | Gene editing for immunological destruction of neoplasia | |
| JP2018522072A5 (https=) | ||
| JP2020518256A5 (https=) | ||
| JP2018500006A5 (https=) | ||
| CN110616189A (zh) | 通用型靶向cd19抗原嵌合受体t细胞的制备及其应用 | |
| CN106817904A (zh) | T细胞平衡基因表达、物质组合物及其使用方法 | |
| Meissner et al. | Genome editing for human gene therapy | |
| JP2020528738A (ja) | ｉｎ ｖｉｔｒｏでＴ細胞中のターゲット遺伝子をノックアウトするための方法及び前記方法で使用されるｃｒＲＮＡ | |
| KR20230035048A (ko) | B 세포에서 b2m 로커스를 편집하는 방법 및 조성물 | |
| US20210002609A1 (en) | Modified lymphocytes | |
| JP2023516538A (ja) | Ｕｃａｒｔ細胞を精製する方法及び応用 | |
| WO2025261230A1 (zh) | 一种工程化的细胞及其应用 | |
| EP4240404A1 (en) | Methods and compositions for eliminating engineered immune cells |